No conviction changes recorded
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
15.0%/yr
±7.5% · revenue growth to justify current price
FCF-Based Reverse DCF
63.0%/yr
±4.4% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~6h).
Eagle will generate this view by the next trading session (~6h).
Major transformation year completed: Qnity spin-off done, Aramids sale pending Q1 2026. Focus now pure-play healthcare/water + industrials. PFAS/litigation overhang remains material. Healthcare segmen...